Pancreatitis of biliary origin: Optimal timiNg CHOlecystectomy (PONCHO) trial

ISRCTN ISRCTN72764151
DOI https://doi.org/10.1186/ISRCTN72764151
Secondary identifying numbers N/A
Submission date
26/05/2010
Registration date
29/06/2010
Last edited
16/10/2015
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Digestive System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Prof H G Gooszen
Scientific

Dutch Pancreatitis Study Group
Department of Surgery
Radboud University Nijmegen Medical Centre
HP 690
PO Box 9101
Nijmegen
6500HB
Netherlands

Phone +31 (0)243 655764 / 66458
Email H.Gooszen@ok.umcn.nl

Study information

Study designMulticentre randomised controlled parallel group superiority trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details below to request a patient information sheet
Scientific titlePancreatitis of biliary origin: Optimal timiNg CHOlecystectomy (PONCHO) trial. A randomised controlled multicentre trial of the Dutch Pancreatitis Study Group.
Study acronymPONCHO
Study objectivesCurrent hypothesis as of 24/04/2012
We hypothesise that early timing of laparoscopic cholecystectomy (ELC) would reduce recurrent biliary pancreatitis or other complications of gall-stone disease in patients with mild biliary pancreatitis.

Study conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO).

Previous hypothesis
We hypothesise that early timing of laparoscopic cholecystectomy (ELC) would prevent recurrent biliary pancreatitis or other complications of gall-stone disease in patients with mild biliary pancreatitis.

Study conducted in accordance with the principles of the Declaration of Helsinki.
Ethics approval(s)Approved by the Arnhem-Nijmegen Regional Committee on Research Involving Human Subjects (Commissie Mensgebonden Onderzoek [CMO] regio Arnhem-Nijmegen).
The study protocol will also be approved by all participating hospitals.
Health condition(s) or problem(s) studiedMild biliary pancreatitis
Intervention1. Intervention group:
Laparoscopic cholecystectomy within 72 hours after randomisation (ELC).
2. Control group:
Laparoscopic cholecystectomy 25-30 days after randomization (ILC).

Patients are randomised when the treating physician feels the patient can be discharged within 1-2 days and all signs of acute disease have resolved.
Intervention typeOther
Primary outcome measureCurrent primary outcome as of 24/04/2012
Composite endpoint: Unplanned re-admission for biliary events (recurrent biliary pancreatitis, acute cholecystitis, choledocholithiasis mandating ERCP, biliary colics) and mortality

Previous primary outcome
Composite endpoint: Unplanned re-admission for biliary events (recurrent biliary pancreatitis, acute cholecystitis, choledocholithiasis mandating ERCP, biliary colics)
Secondary outcome measures1. Individual components of the primary endpoint
2. Number of biliary colics after randomisation
3. Length of hospital stay
4. Operation difficulty (VAS)
5. Duration
6. Complications and conversion rate of laparoscopic cholecystectomy
7. Costs per primary endpoint avoided
8. Quality adjusted life year (QALY) gained
9. Mortality
10. Patient satisfaction
Overall study start date01/01/2011
Completion date01/07/2013

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants266
Key inclusion criteriaCurrent inclusion criteria as of 24/04/2012
1. Age 18 years or older
2. Mild (non-severe) biliary pancreatitis; no pancreatic necrosis and/or peripancreatic collections and no persistent (>48hr) organ failure
3. First episode of acute pancreatitis
4. Written and oral informed consent (obtained prior to randomisation)

Previous inclusion criteria
1. Age 18 years or older
2. Mild (non-severe) biliary pancreatitis, without sterile pancreatic necrosis and/or peripancreatic collections.
3. Written and oral informed consent (obtained prior to randomisation)
Key exclusion criteriaCurent exclusion criteria as of 24/04/2012
1. Patients <18 years
2. Patients >75 years with ASA III
3. ASA IV and V patients
4. Patients with ongoing alcohol abuse or chronic pancreatitis
5. Pregnancy

Previous exclusion criteria
1. Patients <18 years
2. Patients >75 years with ASA III
3. ASA IV and V patients
4. Patients with history of alcohol abuse or chronic pancreatitis
5. Mild pancreatitis with sterile pancreatic necrosis and/or peripancreatic collections
6. Severe pancreatitis: persistent (>48hrs) organ failure or necrotizing pancreatitis
Date of first enrolment01/01/2011
Date of final enrolment01/07/2013

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Dutch Pancreatitis Study Group
Nijmegen
6500HB
Netherlands

Sponsor information

Radboud University Nijmegen Medical Centre (Netherlands)
Hospital/treatment centre

Dutch Pancreatitis Study Group
Department of Surgery
HP 557
PO Box 9101
Mobile: +31 (0)617401029
Nijmegen
6500HB
Netherlands

Website http://www.pancreatitis.nl
ROR logo "ROR" https://ror.org/05wg1m734

Funders

Funder type

Hospital/treatment centre

Radboud University Nijmegen Medical Centre (Netherlands) - internal funding

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 26/11/2012 Yes No
Results article results 26/09/2015 Yes No

Editorial Notes

16/10/2015: Publication reference added.